Dogwood Therapeutics, Inc. (DWTX) - Total Assets
Based on the latest financial reports, Dogwood Therapeutics, Inc. (DWTX) holds total assets worth $91.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dogwood Therapeutics, Inc. - Total Assets Trend (2018–2024)
This chart illustrates how Dogwood Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see how much is Dogwood Therapeutics, Inc. worth for the company's overall valuation and market capitalisation.
Dogwood Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Dogwood Therapeutics, Inc.'s total assets of $91.99 Million consist of 17.5% current assets and 82.5% non-current assets. Review DWTX current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $65.71 Million | 69.7% |
| Goodwill | $11.81 Million | 12.5% |
Asset Composition Trend (2018–2024)
This chart illustrates how Dogwood Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Dogwood Therapeutics, Inc. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dogwood Therapeutics, Inc.'s current assets represent 17.5% of total assets in 2024, a decrease from 64.3% in 2018.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2024, down from 45.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 81.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 69.7% of total assets.
Dogwood Therapeutics, Inc. Competitors by Total Assets
Key competitors of Dogwood Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Dogwood Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.49 | 1.71 | 20.55 |
| Quick Ratio | 4.49 | 1.71 | 20.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.06 Million | $949.43K | $29.94 Million |
Dogwood Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Dogwood Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | 2164.1% |
| Total Assets | $94.31 Million |
| Market Capitalization | $54.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dogwood Therapeutics, Inc.'s assets below their book value (0.58x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Dogwood Therapeutics, Inc.'s assets grew by 2164.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dogwood Therapeutics, Inc. (2018–2024)
The table below shows the annual total assets of Dogwood Therapeutics, Inc. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $94.31 Million | +2164.06% |
| 2023-12-31 | $4.17 Million | -50.23% |
| 2022-12-31 | $8.37 Million | -46.95% |
| 2021-12-31 | $15.78 Million | -49.87% |
| 2020-12-31 | $31.47 Million | +9862.88% |
| 2019-12-31 | $315.90K | +379.11% |
| 2018-12-31 | $65.94K | -- |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-… Read more